Do Wegovy & Ozempic Protect the Heart? (The SELECT Trial)

"Does Ozempic protect your heart?" is one of the most consequential questions you can ask about these drugs — and also one of the easiest to get wrong. The headline version ("semaglutide is good for your heart") is roughly true but dangerously incomplete. The cardiovascular benefit is real, randomized, and FDA-recognized — but it was proven in a specific population, not in everyone who picks up a pen. This guide walks through exactly what the SELECT trial found, who it applies to, why it probably works, and where the evidence stops. It is general education, not medical advice for your situation.

First, the grounding fact: Wegovy and Ozempic are both semaglutide, the same GLP-1 receptor agonist molecule from the same manufacturer (Novo Nordisk), sold under two brand names for two different approved uses — diabetes for Ozempic, chronic weight management for Wegovy. We unpack that distinction in Ozempic vs Wegovy: same drug, different label. It matters here because the cardiovascular indication and most of the cardiovascular trial evidence sit on the Wegovy (weight-management) side, at the 2.4 mg dose.

The SELECT trial: what it actually showed

The landmark study is SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in the New England Journal of Medicine in 2023. It enrolled 17,604 adults who had three things in common: they were 45 or older, they had overweight or obesity (BMI ≥27), and — critically — they had established cardiovascular disease (a prior heart attack, prior stroke, or symptomatic peripheral artery disease). Just as importantly, they did not have diabetes. Participants were randomized to weekly semaglutide 2.4 mg (the Wegovy dose) or placebo, on top of standard heart-disease care, and followed for over three years¹.

The result was the headline that reshaped the field: semaglutide reduced the risk of major adverse cardiovascular events — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — by 20% versus placebo (6.5% of the semaglutide group had an event vs 8.0% on placebo)¹. That is a clinically meaningful reduction in hard endpoints — not a surrogate marker like a lab value, but actual heart attacks, strokes, and deaths prevented.

This is the result that earned semaglutide an entirely new kind of approval.

The FDA cardiovascular indication (and its exact wording)

In March 2024, the FDA approved a cardiovascular indication for Wegovy on the strength of SELECT. The label is precise, and the precision is the whole point. Wegovy is indicated, alongside a reduced-calorie diet and increased physical activity, "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight"².

Read that carefully, because the qualifiers are not boilerplate. The approved population is people who already have cardiovascular disease and overweight or obesity. The indication does not say "anyone taking semaglutide gets heart protection," and it does not extend to people who are simply at elevated risk but have no established disease. SELECT did not test those groups, so the benefit in them is unproven — a genuine evidence gap, not a technicality.

This is the single most common way the SELECT story gets distorted in marketing and headlines: a benefit proven in secondary prevention (people with known heart disease) gets quietly generalized into primary prevention (preventing a first event in healthy-but-overweight people). The trial does not license that leap.

Why does it work? More than just weight loss

A fair question: is the heart benefit just because people lost weight? Losing weight is itself good for the cardiovascular system, and SELECT participants did lose a meaningful amount — roughly 10% of body weight on average, sustained over years³. (Because that benefit accrued over years of continued use, it is one of the strongest arguments for long-term treatment — see how long should you stay on semaglutide?.) Obesity is a well-established driver of cardiovascular disease and death⁴, so some of the benefit surely flows through weight.

But the evidence suggests weight loss is not the whole story. Two clues point to direct, weight-independent effects:

First, the timing. In SELECT, the curves for cardiovascular events began to separate early — before most of the weight loss had accumulated — which is hard to explain by weight reduction alone.

Second, the magnitude relative to weight lost. The 20% risk reduction is larger than you'd expect from ~10% weight loss based on older weight-loss data, hinting at additional mechanisms.

Mechanistically, GLP-1 receptor agonists appear to act on the cardiovascular system through several routes beyond appetite: reducing vascular inflammation, improving endothelial (blood-vessel-lining) function, lowering blood pressure, and improving lipids and glycemic control — a multi-pronged effect summarized in a 2023 Nature Reviews Cardiology review of the class⁵. Supporting the "more than weight" interpretation, a SELECT analysis found the cardiovascular benefit was present regardless of baseline HbA1c and regardless of change in HbA1c, meaning it wasn't simply a glucose-lowering effect⁶.

The honest summary: the heart benefit is real and partly independent of weight loss — but the exact contribution of each mechanism is still being worked out.

The diabetes side: SUSTAIN-6 came first

SELECT wasn't the first signal. Back in 2016, the SUSTAIN-6 trial tested semaglutide (at the lower diabetes doses, up to 1.0 mg — the Ozempic range) in 3,297 people with type 2 diabetes at high cardiovascular risk. It found a 26% reduction in major adverse cardiovascular events versus placebo, driven mainly by fewer non-fatal strokes⁷.

That trial is why Ozempic's own label carries a cardiovascular indication for adults with type 2 diabetes and established cardiovascular disease. But SUSTAIN-6 came with an honest caveat that responsible coverage shouldn't bury: it found a higher rate of diabetic retinopathy complications in the semaglutide group⁷ — a signal thought to relate to rapid glucose-lowering in people who already had eye disease, and a reason eye monitoring matters for people with diabetic retinopathy. It's a reminder that "good for the heart" never means "risk-free."

Beyond the heart: kidney and heart-failure signals

The cardiovascular-protection story has expanded into adjacent organ systems, which strengthens the overall picture of semaglutide as a cardio-renal-metabolic drug — with the same caveat that each finding applies to the population actually studied.

In the FLOW trial (2024), semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease reduced the risk of major kidney events — including kidney failure and death — by 24%, a result that earned a new FDA kidney indication in January 2025⁸. (We cover that approval in Ozempic for kidney disease: what the FLOW trial showed, and the broader renal picture — including the separate short-term dehydration concern — in semaglutide and your gallbladder & kidneys.)

And in a 2024 pooled analysis of SELECT, FLOW, and the STEP-HFpEF heart-failure trials, semaglutide reduced heart-failure-related events in people with heart failure with preserved or mildly reduced ejection fraction⁹ — another population-specific benefit, not a blanket one. The dedicated HFpEF trials behind that signal, and the important distinction between proven symptom benefit and unproven hard outcomes, are covered in Wegovy and heart failure (HFpEF): what the evidence says.

What this does — and doesn't — mean for you

Here is the honest bottom line, separated into what the evidence supports and where it stops.

What's proven: In adults with established cardiovascular disease plus overweight or obesity, semaglutide 2.4 mg (Wegovy) reduces the risk of heart attack, stroke, and cardiovascular death by about 20% — a randomized, FDA-recognized benefit¹². In people with type 2 diabetes at high cardiovascular risk, the diabetes-dose semaglutide (Ozempic range) reduces those events too⁷.

What's not proven: That semaglutide protects the heart of someone who is overweight but has no cardiovascular disease and no diabetes (primary prevention was not tested). That it benefits people outside the trial BMI and age criteria. That compounded semaglutide — which was never the molecule studied in SELECT — delivers the same cardiovascular outcome. The trial efficacy applies to the FDA-approved branded product used as studied; real-world results vary with adherence, dose, and who's actually taking it.

The framing that matters: This is a prescription-only medicine with real benefits and real risks (gastrointestinal effects, gallbladder disease, the retinopathy signal in diabetes, and more — see semaglutide dosing & side effects). One effect that surprises people is that the same drug raises resting heart rate by a few beats per minute even as it lowers cardiovascular events — we reconcile that apparent paradox in does Wegovy or Ozempic raise heart rate?. The cardiovascular benefit is a reason it's a serious therapeutic tool for the right person — not a reason to treat it as a heart-health supplement for everyone. Whether you fit the population SELECT studied, and whether the benefit outweighs the risks for you, is a conversation for your clinician.

The heart is not the only organ where semaglutide earned a new indication on its own dedicated trial — in 2025 it also became the first GLP-1 approved for fatty-liver disease; see Wegovy for MASH (fatty liver): the new FDA approval. For the complete picture of how semaglutide works, what results to expect, and the full safety profile, start with our pillar guide, Semaglutide: how it works, results & side effects. And if you're weighing providers, our editorial ranking is at the best semaglutide options, rated.